Internet Archive Scholar

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Manik Garg, Dominique Couturier, Jérémie Nsengimana, Nuno A Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran B Jönsson, Julia Newton-Bishop, Christine Parkinson, Mark R Middleton, D Timothy Bishop (+15 others)
2021

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (4.8 MB)
https://web.archive.org/web/20210501102807/https://www.repository.cam.ac.uk/bitstream/handle/1810/319695/Tumour%20gene%20expression%20signature%20in%20primary%20melanoma%20predicts%20long-term%20outcomes.pdf;jsessionid=B9A7B9E94AF5C13225BDB1947E5E77F3?sequence=1

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

Adjuvant systemic therapies are now routinely used following resection of stage III melanoma, however accurate prognostic information is needed to better stratify patients. We use differential expression analyses of primary tumours from 204 RNA-sequenced melanomas within a large adjuvant trial, identifying a 121 metastasis-associated gene signature. This signature strongly associated with progression-free (HR = 1.63, p = 5.24 × 10 −5 ) and overall survival (HR = 1.61, p = 1.67 × 10 −4 ), was
more » ... idated in 175 regional lymph nodes metastasis as well as two externally ascertained datasets. The machine learning classification models trained using the signature genes performed significantly better in predicting metastases than models trained with clinical covariates (p AUROC = 7.03 × 10 −4 ), or published prognostic signatures (p AUROC < 0.05). The signature score negatively correlated with measures of immune cell infiltration (ρ = −0.75, p < 2.2 × 10 −16 ), with a higher score representing reduced lymphocyte infiltration and a higher 5-year risk of death in stage II melanoma. Our expression signature identifies melanoma patients at higher risk of metastases and warrants further evaluation in adjuvant clinical trials.
doi:10.17863/cam.66816 fatcat:el2bfceuprgubcr5szazaukjiy
Open Access
Citation

Manik Garg, Dominique Couturier, Jérémie Nsengimana, Nuno A Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran B Jönsson, Julia Newton-Bishop, Christine Parkinson, Mark R Middleton, D Timothy Bishop, Sarah McDonald, Nikki Stefanos, John Alphonse Tadross, Ismael A Vergara, Serigne Lo, Felicity Newell, James S Wilmott, John F Thompson, Georgina V Long, Richard A Scolyer, Pippa Corrie, David J Adams, Alvis Brazma, Roy Rabbie, Apollo-University Of Cambridge Repository. "Tumour gene expression signature in primary melanoma predicts long-term outcomes." (2021)